

Coronavirus Disease 2019 (COVID-19) Situation Report



Weekly Report No. 226 - Saudi Arabia

04 -10 February, 2021

	Global		Eastern Mediterranean Region	
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths
Current	106,555,206	2,333,446	5,898,784	138,069
Last Week	103,362,039	2,244,713	5,734,663	135,359
In 7 days	3,193,167	88,733	164,121	2,710

Saudi Arabia

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests
Total	371,356	362,368	6,415	2,573	417	12,797,144
In 7 days	2,411	1,968	29	-	-	353,188
03/02/21	303	297	3	2,162	395	54,851
04/02/21	327	257	4	2,228	385	54,056
05/02/21	386	283	4	2,327	401	45,874
06/02/21	317	278	5	2,361	408	46,166
07/02/21	356	298	4	2,415	401	48,260
08/02/21	353	249	4	2,515	427	53,039
09/02/21	369	306	5	2,573	417	50,942

HIGHLIGHTS

- Regions with the highest new infections over the past 7 days: Riyadh (1,072), Eastern (537), Makkah (311), Madinah (95), Al Bahah (91), Asir (59), Al Qassim (56), and Najran (42).
- Suspending all activities in the diving centers and on the beaches for 1 week starting from Monday, February 8.
- Imam Abdul Rahman Bin Faisal University has started the first phase of clinical trials to produce the coronavirus vaccine.
- Ministry of Interior: Spreading false information via social media about Corona virus would cause a fine not exceeding 1,000,000 riyals or imprisonment for a period of not less than 1 year and not more than 5 years or both.
- More than 84,000 field visits were carried out on restaurants, markets and commercial establishments in the Kingdom that have resulted in the detection of more than 13,000 violations. A total of 3,000 establishments have been closed down for coronavirus protocol violations from Feb.2 to 8.
- MoH: The second dose of the Corona vaccine should be from the same company of the first dose, 3 to 6 weeks between them will give the needed effect.
- SCDC publishes the guideline for quarantine and medical isolation, and the mechanism for dealing with people coming from abroad, see link.
- WHO publishes new Essential Diagnostics List and urges countries to prioritize investments in testing.
- WHO updated clinical case management guideline for COVID-19.
- WHO provides Interim recommendations for use of the Moderna COVID-19 vaccine, see link.
- WHO publishes Interim recommendations for the use of the Pfizer–BioNTech COVID-19 vaccine, under Emergency Use Listing, see link.
- WHO developed an online global consultation on contact tracing in the context of COVID-19, see link.

IMPORTANT LINKS





- **MoH COVID-19 updates:** <https://twitter.com/saudimoh>
- **WHO's COVID-19 global situation reports:** <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>
- **WHO's COVID-19 dashboard:** <https://covid19.who.int/>
- **MoH COVID-19 dashboard:** <https://covid19.my.gov.sa/ar/Pages/default.aspx>
- **SCDC's guideline for quarantine, medical isolation and the mechanism for dealing with people coming from abroad :** https://covid19.cdc.gov.sa/wp-content/uploads/2021/02/AR_guideline_for_quarantine_and_isolation.pdf
- **WHO's new essential diagnostics list:** <https://www.who.int/news/item/29-01-2021-who-publishes-new-essential-diagnostics-list-and-urges-countries-to-prioritize-investments-in-testing>
- **WHO's COVID-19 Clinical management living guidance:** <https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1>
- **Interim recommendations for use of the Moderna vaccine:** <https://www.who.int/publications/i/item/interim-recommendations-for-use-of-the-moderna-mrna-1273-vaccine-against-covid-19>
- **Interim recommendations for the use of the Pfizer–BioNTech COVID-19 vaccine, under Emergency Use Listing:** https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-BNT162b2-2021.1
- **Online global consultation on contact tracing in the context of COVID-19:** <https://www.who.int/publications/i/item/online-global-consultation-on-contact-tracing-for-covid-19-9-11-june-2020>
- **Draft landscape and tracker of COVID-19 candidate vaccines:** <https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines>

IMPORTANT DEVELOPMENTS

WHO provides interim guidance on the use of the Moderna COVID-19 vaccine:

This interim guidance has been developed on the basis of the advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) at its extraordinary meeting on 21 January 2021. The mRNA-1273 vaccine against COVID-19 developed by Moderna (Moderna COVID-19 vaccine) has been shown to have an efficacy of 94.1%, based on a median follow-up of two months. High efficacy was maintained across all age groups (above 18 years), and was not affected by sex or ethnicity. The data reviewed by WHO at this time support the conclusion that the known and potential benefits of the vaccine outweigh the known and potential risks. Intended use: Persons aged 18 years and above. The recommended schedule is two doses (0.5 ml each) given intramuscularly into the deltoid muscle. An interval of 28 days between doses is recommended. There is currently no evidence on the need for a booster dose or booster doses of the vaccine after the current two-dose vaccine series is complete. There should be a minimum interval of 14 days between administration of this vaccine and any other vaccine. A history of anaphylaxis to any component of the vaccine is a contraindication to vaccination. If anaphylaxis occurs after the first dose, a second dose of the Moderna vaccine or of the Pfizer/BioNTech should not be administered. Vaccination is recommended for older persons and persons with comorbidities. As with the Pfizer/BioNTech vaccine, mitigation measures (including use of face masks, physical distancing, handwashing) should continue to be followed by vaccinated individuals.

Vaccination logistics: The vaccine is provided as a frozen suspension at -25°C to -15°C in a multidose vial containing 10 doses. The vaccine must be thawed prior to administration. After thawing, vials can be stored refrigerated at $2-8^{\circ}\text{C}$ for up to 30 days prior to withdrawal of the first dose. Unopened vials may be stored for up to 12 hours in cool storage or at room temperature ($8-25^{\circ}\text{C}$). After the first dose has been withdrawn, the vial should be held between 2°C and 25°C and discarded after 6 hours. For more details, see link.



IMPORTANT CONTACTS

- The National Focal Person for COVID-19 is Dr Abdullah Asiri, Assistant Deputy for Preventive Health, MoH, email: AbdullahM.Asiri@moh.gov.sa